GlycoVaxyn has secured exclusive, worldwide rights from the Swiss Federal Institute of Technology (ETH) to its proprietary technology (Patents 1 & 2 in Figure 5).
GlycoVaxyn is aggressively supplementing and strengthening its intellectual property position by submitting national patent applications in a number of countries. Figure 5 illustrates the company's IP portfolio.
Figure 5: GlycoVaxyn IP portfolioPatent Title |
Priority Date |
Status |
| System and method for the production of recombinant glycosylated proteins in a prokaryotic host | 3/14/2002 | Granted patents in JP, AU, EP, KR, SG; pending patents in CA, IL, IN and US |
| Recombinant N-glycosylated proteins from procaryotic cells | 5/11/2005 | Granted patents in EP and SG, AU; pending patents in CN, CA, IL, IN, JP, KR, US |
| Production of a glycoconjugated shigella vaccine | 2/20/2008 | National phase |
| Biosynthetic system that produces antigenic polysaccharides in prokaryotic cells | 11/19/2010 | PCT application |
| Capsular Gram-Positive Bioconjugate Vaccines | 5/6/2010 | US non-provisional / PCT application |
